HR and breast carcinoma: There are two ongoing phase III studies of CDK4/6 inhibitors applied to the adjuvant treatment of HR+/HER2- early breast cancer, dalpiciclib (SHR6390-III-303, NCT04842617) and TQB3616 (TQB3616-III-03, NCT05780567).